DentalCare Logo

Cardiovascular Drugs Our Patients Take

Course Number: 581

PDF

References / Additional Resources

  1. Terézhalmy GT, Huber MA, Garcia Lt, Occhionero RL. Physical evaluation in dental practice, 2nd ed. Hoboken, NJ. Wiley-Blackwell. 2021.

  2. ClinCalc DrugStats Data Base. Accessed January 3, 2023.

  3. Krisko TI, Armstrong EJ, Cohen DE. Pharmacology of Cholesterol and Lipoprotein Metabolism. Principles of Pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 336-357.

  4. Toka HR, Alper SL. Pharmacology of Volume Regulation. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 358-384.

  5. Oldham WM, Loscalzo J. Pharmacology of Vascular Tone. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 385-401.

  6. Gera N, Armstrong EJ, Golan DE. Adrenergic Pharmacology. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 150-166.

  7. Armstrong EJ, Golan DE. Pharmacology of Cardiac Rhythm. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 433-453.

  8. Armstrong EJ. Pharmacology of Cardiac Contractility. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 454-468.

  9. Armstrong EJ, Golan DE. Pharmacology of Hemostasis and Thrombosis. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 403-432.

  10. U.S. National Library of Medicine. DailyMed. Accessed January 3, 2023.

  11. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Accessed January 3, 2023.

  12. Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2019 May 28; 73(20): 2584–2595. doi:10.1016/j.jacc.2019.03.467.

  13. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity. Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 70-86.

  14. Williams KA, Taifour ML, Huber MA. Adverse Drug Reactions - Part I. dentalcare.com Accessed January 3, 2023.

  15. Williams KA, Taifour ML, Huber MA. Adverse Drug Reactions - Part II. dentalcare.com. Accessed January 3, 2023.

  16. Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, et al. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021 Nov 11;8:754499. doi: 10.3389/fcvm.2021.754499.

  17. McCabe JM, Armstrong EJ. Interactive Cardiovascular Pharmacology: Hypertension, Ischemic Heart Disease, and Heart Failure. The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 469-496.

    Whelton PK, Carey RM, Aronow WS, et al. 2017

  18. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13.

  19. Huber MA, Ojeda Diaz DL. Hypertension: Risk Stratification and Patient Management in Oral Healthcare Settings. dentalcare.com Accessed February 21, 2019.

  20. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.

  21. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989 Sep 15;64(10):651-4.

  22. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001 Oct 2;104(14):1694-740.

  23. Reilly DF, McNeely MJ, Doerner D, et al. Self-reported Exercise Tolerance and the Risk of Serious Perioperative Complications. Arch Intern Med. 1999 Oct 11;159(18):2185-92.

  24. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014 Dec 9;64(22):e77-137. doi: 10.1016/j.jacc.2014.07.944. Epub 2014 Aug 1.

  25. Drugs for Chronic Heart Failure. Med Lett Drug Ther 2021; June 14 (epub).

  26. Bajkin BV, Urosevic IM, Stankov KM, et al. Dental extractions and risk of bleeding in patients taking single and dual antiplatelet treatment. Br J Oral Maxillofac Surg. 2015 Jan;53(1):39-43. doi: 10.1016/j.bjoms.2014.09.009. Epub 2014 Oct 11.

  27. Wahl MJ, Pinto A, Kilham J, et al. Dental surgery in anticoagulated patients--stop the interruption. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Feb;119(2):136-57. doi: 10.1016/j.oooo.2014.10.011. Epub 2014 Nov 13.

Additional Resources


No Additional Resources Available

0/16Next